Valuation: Black Diamond Therapeutics, Inc.

Market Cap 10Cr 9.19Cr 8.53Cr 7.84Cr 15Cr 1.01TCr 15Cr 101.61Cr 40Cr 495.12Cr 39Cr 39Cr 1.71TCr P/E 2026 *
-2.83x
P/E 2027 * -1.82x
Enterprise Value 10Cr 9.19Cr 8.53Cr 7.84Cr 15Cr 1.01TCr 15Cr 101.61Cr 40Cr 495.12Cr 39Cr 39Cr 1.71TCr EV / Sales 2026 *
18.9x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day-2.14%
1 week+1.10%
Current month-1.08%
1 month+13.66%
3 months-45.37%
6 months-30.94%
Current year-24.69%
1 week 1.77
Extreme 1.77
1.9
1 month 1.61
Extreme 1.61
2.22
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Free

Director

40,000 0.0698%
26/06/26 Free

Director

40,000 0.0698%
26/06/26 Free

Director

40,000 0.0698%
Change 5-day change 1-year change 3-year change Capi.($)
-2.14%+1.10%-42.63%-59.33% 10Cr
-0.43%-4.26%+52.09%+85.69% 5.53TCr
-0.24%+1.04%+55.76%+54.21% 5.42TCr
-1.82%-2.89%+3.61%+405.88% 2.31TCr
-0.54%-0.17%-17.60%-15.43% 2.32TCr
+0.31%-0.92%+35.51%-3.92% 2.03TCr
+3.16%+0.79%+37.98%-31.36% 1.79TCr
+0.58%-0.48%+38.67%+551.63% 1.58TCr
+0.43%-10.61%+175.63%+299.61% 1.5TCr
-2.03%-1.03%+23.63%+179.23% 1.38TCr
Average -0.27%-0.53%+36.27%+146.62% 2.39TCr
Weighted average by Cap. -0.17%-0.44%+44.16%+132.86%

Financials

2026 *2027 *
Net sales 55.56L 48.68L 45.19L 41.53L 78.25L 54Cr 79.4L 5.38Cr 2.11Cr 26Cr 2.09Cr 2.04Cr 91Cr -
Net income -4.05Cr -3.55Cr -3.29Cr -3.03Cr -5.7Cr -390.54Cr -5.78Cr -39Cr -15Cr -191.1Cr -15Cr -15Cr -660.15Cr -7Cr -6.14Cr -5.7Cr -5.24Cr -9.87Cr -675.9Cr -10Cr -68Cr -27Cr -330.73Cr -26Cr -26Cr -1.14TCr
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
22/26/22 $1.830 -2.14% 5,20,329
21/26/21 $1.870 +3.31% 4,90,389
20/26/20 $1.810 +1.12% 6,95,830
17/26/17 $1.790 -1.10% 7,08,209
16/26/16 $1.810 0.00% 8,55,858
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.830USD
Average target price
9.857USD
Spread / Average Target
+438.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock